Metapex
Phase 1Small molecule
Metapex is one of 49 small molecule programs targeting Pulpitis. It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
138 competitors in Periodontitis
#DrugCompanyPhaseTrials
1Peridex
DDexcel Pharma Technologies Ltd.
Phase 3
Acanya
PfizerPhase 3
Curcumin
Merck & Co.Phase 3
Calcium Hydroxide
MMansoura University
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 2
Docosahexaenoic Acid
MMicelle BioPharma Inc
Phase 2
Calcium Intravenous Infsuion
MMansoura University
Phase 3
Minocycline Hcl
OOraPharma
Phase 3
Boswellia
MMansoura University
Phase 3
Leddermix
MMansoura University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Periodontitis1 trial
Comparison of Anti-microbial Efficacy of Calcipex and Metapex in Endodontic Treatment of Chronic Apical Periodontitis
Completed·—·Phase 2/3·NCT04336709·60 enrolled
Pulpitis1 trial
Comparison of 3Mixtatin Pulpotomy and Metapex Pulpectomy in Primary Molars With Irreversible Pulpitis
Not yet recruiting·—·Phase 1·NCT06925490·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metapex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAga Khan University